A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
23 11 2021
23 11 2021
Historique:
received:
18
03
2021
accepted:
04
07
2021
pubmed:
21
9
2021
medline:
30
11
2021
entrez:
20
9
2021
Statut:
ppublish
Résumé
Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet, empirical knowledge about the treatment of older patients is limited because they are frequently excluded from clinical trials. We aimed to construct a simplified frailty score and examine survival and treatment-related mortality (TRM) according to frailty status and treatment intensity in an older real-world population with DLBCL. All patients aged ≥70 years diagnosed with DLBCL between 2006 and 2016 in southeastern Norway (N = 784) were included retrospectively and divided into training (n = 522) and validation (n = 262) cohorts. We constructed and validated a frailty score based on geriatric assessment variables and examined survival and TRM according to frailty status and treatment. The frailty score identified 3 frailty groups with distinct survival and TRM, independent of established prognostic factors (2-year overall survival [OS]: fit, 82%; unfit, 47%; frail, 14%; P < .001). For fit patients, full-dose R-CHOP (initial dosage >80%) was associated with better survival than attenuated R-CHOP ([R-miniCHOP]; 2-year OS: 86% vs 70%; P = .012), also in adjusted analyses. For unfit and frail patients, full-dose R-CHOP was not superior to R-miniCHOP, whereas an anthracycline-free regimen was associated with poorer survival in adjusted analyses. A simplified frailty score identified unfit and frail patients with a higher risk for death and TRM, which can aid treatment-intensity decisions in older patients with DLBCL. In this study, fit patients benefited from full-dose R-CHOP, whereas unfit and frail patients had no benefit from full-dose R-CHOP over R-miniCHOP. An online calculator for assessment of the frailty score is available at https://wide.shinyapps.io/app-frailty/.
Identifiants
pubmed: 34543384
pii: 476962
doi: 10.1182/bloodadvances.2021004777
pmc: PMC8759139
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4771-4782Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Am J Clin Nutr. 2005 Oct;82(4):777-83
pubmed: 16210706
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
Blood. 2017 Nov 16;130(20):2180-2185
pubmed: 28814386
Blood. 2015 Mar 26;125(13):2068-74
pubmed: 25628469
Haematologica. 2018 Aug;103(8):1345-1350
pubmed: 29748444
Lancet Haematol. 2017 Jan;4(1):e46-e55
pubmed: 28041583
Br J Cancer. 2011 Nov 22;105(11):1684-92
pubmed: 22045184
J Am Geriatr Soc. 2012 Aug;60(8):1487-92
pubmed: 22881367
Br J Haematol. 2021 Jan;192(1):75-81
pubmed: 32400004
J Clin Oncol. 2013 Oct 10;31(29):3711-8
pubmed: 24019549
Lancet Oncol. 2013 May;14(6):525-33
pubmed: 23578722
Leuk Lymphoma. 2015 Apr;56(4):921-6
pubmed: 25110825
J Clin Oncol. 2021 Apr 10;39(11):1214-1222
pubmed: 33577377
Eur J Haematol. 2016 Apr;96(4):409-16
pubmed: 26084899
J Geriatr Oncol. 2015 May;6(3):211-8
pubmed: 25614297
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
J Clin Oncol. 1991 Jan;9(1):191-2
pubmed: 1985169
Lancet Oncol. 2011 May;12(5):460-8
pubmed: 21482186
Eur J Cancer. 2018 Aug;99:86-96
pubmed: 29935491
Nutr Cancer. 2021;73(3):391-403
pubmed: 32321298
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Intern Med. 2019 Jun;285(6):681-692
pubmed: 30811713
Oncologist. 2000;5(3):224-37
pubmed: 10884501
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Lancet Oncol. 2014 Aug;15(9):931-42
pubmed: 25030467
Leuk Res. 2014 Mar;38(3):275-83
pubmed: 24439052
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
J Am Geriatr Soc. 1983 Dec;31(12):721-7
pubmed: 6418786
Br J Haematol. 2016 May;173(3):487-91
pubmed: 26223361
Eur J Cancer. 2009 May;45(7):1218-1231
pubmed: 19091545
Am J Clin Nutr. 1988 Feb;47(2 Suppl):357-65
pubmed: 3124597
Ann Oncol. 2018 Mar 1;29(3):544-562
pubmed: 29194473
J Clin Oncol. 2012 Jun 10;30(17):2036-8
pubmed: 22547597
Cancer. 2016 Oct 15;122(20):3145-3151
pubmed: 27351173
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
Haematologica. 2020 Jun;105(6):1484-1493
pubmed: 32381581
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Ann Hematol. 2018 Jun;97(6):999-1007
pubmed: 29427185
J Geriatr Oncol. 2020 Jan;11(1):37-40
pubmed: 31296461
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
Lancet Oncol. 2008 Feb;9(2):105-16
pubmed: 18226581
Crit Rev Oncol Hematol. 2000 Sep;35(3):147-54
pubmed: 10960797
Oncologist. 2014 Oct;19(10):1069-75
pubmed: 25170014
Leuk Lymphoma. 2012 Apr;53(4):581-8
pubmed: 21895543
J Geriatr Oncol. 2015 Mar;6(2):141-52
pubmed: 25491101